Two drugs are no more effective than 1 to treat common kidney disease

November 15, 2014

Using two drugs was no more effective than a single drug in slowing disease progression in people with autosomal dominant polycystic kidney disease (ADPKD), according to two studies funded by the National Institutes of Health (NIH). One of the studies also showed that rigorous blood pressure treatment slowed growth of kidney cysts, a marker of ADPKD, but had little effect on kidney function compared to standard blood pressure treatment.

The results of the HALT-PKD Clinical Trials Network studies will be published online November 15 in two papers in the New England Journal of Medicine to coincide with presentation at the American Society of Nephrology annual meeting.

"Enlarged cysts in kidneys can lead to reduced kidney function and eventually kidney failure, where the only treatment is dialysis or transplantation," said study author Michael Flessner, M.D., Ph.D., a program director at the NIH's National Institute of Diabetes and Digestive and Kidney Diseases, which funded the trial. "The HALT-PKD findings show that people with polycystic kidney disease do not need to take both of the drugs studied to slow their rate of kidney cyst growth and decline in kidney function."

The HALT-PKD trial enrolled volunteers to test whether a combination of commonly used FDA-approved drugs, lisinopril and telmisartan, could shrink kidney cysts and therefore slow progression of ADPKD, a genetic disorder characterized by growth of fluid-filled cysts in the kidneys. Within the trial, one study examined 558 people with early-stage ADPKD and relatively healthy kidneys. The other study treated 486 people with more advanced disease and decreased kidney function. In each study, half of participants were randomly assigned to receive lisinopril and telmisartan, while the other half received lisinopril plus a placebo. In both studies, adding the second drug did not change kidney function or rate of increase in kidney cyst size.

In the study of people with early ADPKD and healthy kidneys, researchers also tested if decreasing blood pressure below usual targets would slow progression of ADPKD and preserve kidney function. High blood pressure is a common and damaging effect of ADPKD. Half the participants were assigned to a standard blood pressure group (between 120-130 over 70-80), and half to a lower blood pressure group (between 95-110 over 60-75) but still within the normal range.

Participants in the lower blood pressure group received more rigorous treatment, taking more medication to maintain a lower blood pressure. The lower blood pressure group had a 14 percent decrease in kidney cyst size compared to those in the standard blood pressure group. However, kidney function - measured by estimated glomerular filtration rate (eGFR) - was about the same as the standard group at the end of the trial, yielding no clinical benefit. About 15 percent more of the people in the lower blood pressure group experienced lightheadedness and dizziness.

"The HALT-PKD studies were well performed and the largest of their kind," said Robert Star, M.D., director of the Division of Kidney, Urologic, and Hematologic Diseases within NIDDK. "More research is needed to better understand how polycystic kidney disease destroys kidney function over time, and what combination of medications can most safely and effectively prevent or undo the damage caused by this devastating condition."

ADPKD is the most common kind of polycystic kidney disease, representing 90 percent of the approximately 600,000 U.S. cases. PKD is the fourth leading cause of kidney failure.
HALT-PKD (tkNCT#) was supported by NIDDK under grants DK62408, DK62401, DK62410, DK62402, DK62411 and DK082230, with additional support from the NIH's NCATS under grants RR000039, RR000585, RR000054, RR000051, RR023940, RR001032, RR025008, TR000454, RR024150, TR00135, RR025752, TR001064, RR025780, TR001082, RR025758, TR001102, RR033179, TR000001, RR024989 and TR000439 and the PKD Foundation. Study drugs were donated by Boehringer Ingelheim and Merck & Co., Inc.

The NIDDK, a component of the NIH, conducts and supports research on diabetes and other endocrine and metabolic diseases; digestive diseases, nutrition and obesity; and kidney, urologic and hematologic diseases. Spanning the full spectrum of medicine and afflicting people of all ages and ethnic groups, these diseases encompass some of the most common, severe and disabling conditions affecting Americans. For more information about the NIDDK and its programs, see

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

NIH...Turning Discovery Into Health®

NIH/National Institute of Diabetes and Digestive and Kidney Diseases

Related Kidney Failure Articles from Brightsurf:

UC research finds low rates of contraceptive use in women with kidney failure
New research from the University of Cincinnati finds that women with kidney failure have low rates of contraceptive use.

Why do minorities have higher rates of kidney failure?
A new study indicates that Blacks and Hispanics have experienced higher rates of kidney failure compared with whites due to more rapid kidney function decline.

The economic burden of kidney transplant failure in the United States
A recent analysis published in the American Journal of Transplantation estimates that for the average US patient who has undergone kidney transplantation, failure of the transplanted organ (graft failure) will impose additional medical costs of $78,079 and a loss of 1.66 quality-adjusted life years.

Heart disease linked to a higher risk of kidney failure
In adults followed for a median of 17.5 years, cardiovascular diseases--including heart failure, atrial fibrillation, coronary heart disease, and stroke--were each linked with a higher risk of developing kidney failure.

Compound offers prospects for preventing acute kidney failure
Russian researchers from the Moscow Institute of Physics and Technology, the Institute of Cell Biophysics, and elsewhere have shown an antioxidant compound known as peroxiredoxin to be effective in treating kidney injury in mice.

New study confirms protective effect of diabetes drugs against kidney failure
A new meta-analysis published in Lancet Diabetes and Endocrinology has found that SGLT2 inhibitors can reduce the risk of dialysis, transplantation, or death due to kidney disease in people with type 2 diabetes.

Is kidney failure a man's disease?
A new analysis of the ERA-EDTA Registry [1] reveals a striking gender difference in the incidence and prevalence of end-stage renal disease.

Kidney failure on the rise in Australians under 50 with type 2 diabetes
A study of more than 1.3 million Australians with diabetes has found that kidney failure is increasing in people with type 2 diabetes aged under 50 years, leading to reduced quality of life and placing growing demand on the country's kidney dialysis and transplantation services.

Frailty may lower kidney failure patients' likelihood of receiving a transplant
Frailty is associated with decreased access at multiple stages in the pathway to kidney transplantation.

Obesity surgery prevents severe chronic kidney disease and kidney failure
Patients that underwent weight-loss surgery ran a significantly lower risk of developing severe chronic kidney disease and kidney failure, when compared to conventionally treated patients, according to a study published in International Journal of Obesity.

Read More: Kidney Failure News and Kidney Failure Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to